Leerink analyst Danielle Antalffy believes Johnson & Johnson is "well positioned" to accelerate its device business growth to in line with or better than her currently projected 5% CAGR over the 2015-2020 time-frame, with a broad product pipeline supplementing improving execution and a recover in end user market volumes. The analyst reiterates an Outperform rating and $125 price target on the shares.
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here